Journal
CANCERS
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cancers11050642
Keywords
cannabidiol; TNF-related apoptosis-inducing ligand; death receptor 5; endoplasmic reticulum stress
Categories
Funding
- Business for Cooperative R & D between Industry, Academy, and Research Institute [C0566291]
- Korea University Grant
- National Research Foundation (NRF) of Korea - Korean government (MSIP) [NRF-2015R1D1A1A01058303]
Ask authors/readers for more resources
Cannabidiol, a major non-psychotomimetic compound derived from Cannabis sativa, is a potential therapeutic agent for a variety of diseases such as inflammatory diseases, chronic neurodegenerative diseases, and cancers. Here, we found that the combination of cannabidiol and TNF-related apoptosis-inducing ligand (TRAIL) produces synergistic antitumor effects in vitro. However, this synergistic effect was not observed in normal colonic cells. The levels of ER stress-related proteins, including C/EBP homologous protein (CHOP) and phosphorylated protein kinase RNA-like ER kinase (PERK) were increased in treatment of cannabidiol. Cannabidiol enhanced significantly DR5 expression by ER stress. Knockdown of DR5 decreased the combined effect of cannabidiol and TRAIL. Additionally, the combination of TRAIL and cannabidiol decreased tumor growth in xenograft models. Our studies demonstrate that cannabidiol enhances TRAIL-induced apoptosis by upregulating DR5 and suggests that cannabidiol is a novel agent for increasing sensitivity to TRAIL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available